Colorado Paves the Way for Psychedelic Therapy: New Rules for Psilocybin Industry Take Effect

Colorado Paves the Way for Psychedelic Therapy: New Rules for Psilocybin Industry Take Effect

Colorado has finalized comprehensive regulations for the emerging psilocybin industry, marking a significant step forward in the state’s pioneering efforts to legalize psychedelic therapy. The new rules, which were crafted over two years, provide a framework for businesses to operate in the production, distribution, and therapeutic use of psilocybin, DMT, ibogaine, mescaline, and psilocin, as approved by Proposition 122. This move positions Colorado as a leader in the growing movement to explore the therapeutic potential of psychedelics.

Factor D Complement Inhibitor Market: Growth Driven by Emerging Therapies and Rising Autoimmune Diseases

Factor D Complement Inhibitor Market: Growth Driven by Emerging Therapies and Rising Autoimmune Diseases

The Factor D complement inhibitor market is poised for significant growth, driven by expanding indications for existing therapies like danicopan and the anticipated approval of novel agents like vemircopan. This market expansion is fueled by advancements in biotechnology, increasing prevalence of autoimmune diseases, and a robust pipeline of drug candidates in clinical trials.

India on High Alert for Mpox as WHO Declares Public Health Emergency

India on High Alert for Mpox as WHO Declares Public Health Emergency

Following the World Health Organisation’s declaration of Mpox as a Public Health Emergency, India has taken precautionary measures, including heightened surveillance at airports and land borders, to prevent the spread of the virus. While no cases have been reported in the country, India is closely monitoring the situation and has designated hospitals for managing potential cases.

FDA Lifts Hold on MediLink’s Phase 1 Trial for HER3-Targeting Cancer Drug

FDA Lifts Hold on MediLink’s Phase 1 Trial for HER3-Targeting Cancer Drug

The FDA has lifted a partial clinical hold on MediLink Therapeutics’ Phase 1 trial for BNT326/YL202, a HER3-targeting antibody-drug conjugate (ADC), allowing the trial to resume with adjusted dose levels. The decision follows MediLink’s submission of a complete response addressing FDA concerns regarding potential safety risks at higher doses. The trial will focus on dose levels not exceeding 3 mg/kg, where the treatment has shown a manageable safety profile.

Scroll to Top